Ampicillin
- TRADE NAMES: Amfipen; Ampicin; Binotal; D-Amp; Marcillin; Penbritin; Penstabil; Principen; Pro-Ampi; Sinaplin; Taro-Ampicillin Trihydrate; Totacillin (GSK); Totapen; Vidopen
- INDICATIONS: Susceptible strains of gram-negative and gram-positive bacterial infections
- CLASS: Antibiotic, penicillin
- HALF-LIFE: 1–1.5 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Allopurinol, Anticoagulants, Chloramphenicol, Cyclosporine, Demeclocycline, Doxycycline, Erythromycin, Imipenem/Cilastatin, Levodopa, Methotrexate, Minocycline, Oxytetracycline, Sulfonamides, Tetracycline
PREGNANCY CATEGORY: B
Five to 10% of people taking ampicillin develop eruptions between the 5th and 14th day following initiation of therapy. Also, there is a 95% incidence of exanthematous eruptions in patients who are treated for infectious mononucleosis with ampicillin. The allergenicity of ampicillin appears to be enhanced by allopurinol or by hyperuricemia. Ampicillin is clearly the more allergenic of the two drugs when given alone.
Please login to see the rest of this drug profile
SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
LOCAL
NEUROMUSCULAR/SKELETAL
OTHER
Page last updated 09/06/2019
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
